Dear Doctor - Participate in the Survey on metoprolol " A new survey has found that the vast majority of people who take the blood pressure medication metoprolol are satisfied with the results. The survey, which was conducted by Consumer Reports, polled more than 1,000 people who were taking metoprolol and found that 92% were satisfied with the drug.Metoprolol is a beta-blocker that is typically used to treat hypertension, or high blood pressure. It works by blocking the action of certain hormones in the body that can raise blood pressure. Beta-blockers are some of the most commonly prescribed medications for hypertension, and metoprolol is one of the most popular choices.The Consumer Reports survey found that people who took metoprolol felt it was effective in lowering their blood pressure and reducing their risk of heart attack or stroke. They also reported few side effects from the drug. The most common side effect reported was fatigue, but only 10% of those surveyed said it was a problem for them.Overall, the survey found that metoprolol is an effective and well-tolerated medication for hypertension. If you are taking metoprolol or considering starting on this medication, be sure to speak to your doctor about your specific situation to see if it is right for you. Participate in Surveys "
1.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
2.
More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer
3.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
4.
Mapping lifelong chronic health risks for childhood cancer survivors
5.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
1.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
2.
Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery
3.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
4.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
5.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation